TL02-59 is a Selective and Orally Active Myeloid Src-family Kinase Fgr Inhibitor
Acute myelogenous leukemia (AML) is a devastating hematologic cancer with limited treatments. Scientists have demonstrated that diverse genetic changes are associated with AML. Especially, the upregulation of tyrosine kinase signaling pathways stands for a common feature. Additionally, mutations in the Flt3 receptor tyrosine kinase accounts for almost one-third of...
Multiple Tyrosine Kinases Inhibitor TAS-115
VEGF signaling via VEGF receptor is a pivotal factor for tumor angiogenesis that regulates tumor progression. However, VEGFR-targeted inhibitor monotherapies showed limited effects on various carcinomas. And even combination therapies with chemotherapeutic agents are unsatisfactory. MET is a receptor for HGF. The HGF-MET signaling also participated in regulating tumor progression,...
AZD3229 is a Potent Pan-KIT Mutant Inhibitor
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. While the application of targeted tyrosine kinase inhibitors has revolutionized the treatment of gastrointestinal stromal tumors (GISTs). The targeted tyrosine kinase inhibitors inhibit KIT-driven proliferation, diverse mutations to this kinase drive resistance to established therapies....